Investigational drug · Phase 2
Nadunolimab
Also called: CAN04
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Triple Negative Breast Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: May 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
6
Any phase or sponsor naming "Nadunolimab"
First trial start
2022
Jan 11, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Nadunolimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Triple Negative Breast Cancer
Approved drugs for the same conditions: Breast cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Nadunolimab" as an intervention, largest first.
- Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer.Pivotal-lookingCompleted
Cantargia ABIndustry
NCT05181462 · 117 participants · Start Jan 11, 2022 · Primary completion Apr 9, 2026
Drug: Carboplatin; Gemcitabine and 1 more · For: Triple Negative Breast Cancer
Sites: Granada, Spain; Jaén, Spain; Málaga, Spain · 23 sites in all
Robert SamsteinAcademic, hospital or other
NCT07284485 · 59 participants (planned) · Start May 21, 2026 · Primary completion Dec 15, 2027
Drug: Nadunolimab · For: High-risk Lung Nodules
Sites: New York, New York
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06548230 · 40 participants (planned) · Start Mar 5, 2025 · Primary completion Dec 1, 2027
Drug: Nadunolimab; Azacitidine and 1 more · For: Myelodysplastic Syndrome(MDS); Acute Myelogenous Leukemia (AML)
Sites: Houston, Texas
Cantargia ABIndustry
NCT05116891 · 40 participants · Start Sep 22, 2021 · Primary completion Jun 23, 2023
Drug: CAN04 (nadunolimab); mFOLFOX and 2 more · For: Advanced Solid Tumors; Colorectal Cancer; Non Small Cell Lung Cancer and 1 more
Sites: Saint-Herblain, France; Dijon, France; Bordeaux, France · 6 sites in all
Cantargia ABIndustry
NCT04990037 · 25 participants · Start Jul 19, 2021 · Primary completion May 30, 2023
Drug: CAN04; FOLFIRINOX · For: Metastatic Pancreatic Ductal Adenocarcinoma
Sites: Bordeaux, France; Nantes, France; Rennes, France · 9 sites in all
Dan FengAcademic, hospital or other
NCT07281716 · 24 participants (planned) · Start Dec 1, 2025 · Primary completion Dec 15, 2028
Drug: Nadunolimab; Toripalimab · For: Metastatic Microsatellite Stable Colorectal Carcinoma
Sites: New York, New York
Newest research
PubMed records naming it or its code names, newest first.
- Interleukin-1α (IL-1α) in pancreatic ductal adenocarcinoma: implications for immunotherapy and molecular biomarkers.
Ling K, Xie G, Chen Z, et al. · Clin Transl Oncol 2026
- Letter to the editor: Critical analysis of the CANFOUR trial on nadunolimab in advanced NSCLC.
Yang Z, Liao S · Lung Cancer 2025
- Safety, efficacy, and analysis of biomarkers in patients with advanced non-small cell lung cancer treated with the anti-IL1RAP antibody nadunolimab (CAN04) in combination with platinum doublet.
Paulus A, Zemaitis M, Cicenas S, et al. · Lung Cancer 2025
- Safety, tolerability, and preliminary efficacy of nadunolimab, an anti-IL- 1 receptor accessory protein monoclonal antibody, in combination with pembrolizumab in patients with solid tumors.
Cohen RB, Jimeno A, Hreno J, et al. · Invest New Drugs 2025
- Blocking IL1RAP on cancer-associated fibroblasts in pancreatic ductal adenocarcinoma suppresses IL-1-induced neutrophil recruitment.
Hansen N, Peña-Martínez P, Skoog P, et al. · J Immunother Cancer 2024
- Efficacy and Safety of the Anti-IL1RAP Antibody Nadunolimab (CAN04) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Advanced/Metastatic Pancreatic Cancer.
Van Cutsem E, Collignon J, Eefsen RL, et al. · Clin Cancer Res 2024
Also in development for Triple Negative Breast Cancer
- SerplulimabHLX10, HLX43Phase 325 trials
Shanghai Henlius Biotech · Non Small Cell Lung Cancer, Carcinoma, Hepatocellular, SCLC, Extensive Stage
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- JSKN016Phase 34 trials
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Triple Negative Breast Cancer, Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer
- OBI-821OBI-833Phase 32 trials
OBI Pharma, Inc · Triple Negative Breast Cancer, Non-small Cell Lung Cancer
- FDA018-ADCPhase 31 trial
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. · Triple Negative Breast Cancer
- IL-2MDNA11, Interleukin-2 -albuminPhase 24 trials
Grit Biotechnology · Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma
- BT5528nuzefatide pevedotinPhase 23 trials
BicycleTx Limited · Advanced Solid Tumors, Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer
- BLEX 404 LiquidPhase 22 trials
BioLite, Inc. · Myelodysplastic Syndrome (MDS), Triple Negative Breast Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.